Pay For Delay, There For The Taking?
The most topical constitutional issue implicated by the pharmaceutical industry has been the intersection between off-label promotion and the First Amendment. While we continue to await the U.S. Court of Appeals...To view the full article, register now.
Already a subscriber? Click here to view full article